Sengenics Acquires Oxford Gene Technology’s Protein Array Technology and Announces Global Rebrand to Immunome™
Oxford, England (PRWEB) September 10, 2015 -- Genomics and proteomics-based research and diagnostics company Sengenics today announced its acquisition of Oxford Gene Technology’s (OGT) protein array technology, a patented auto-antibody profiling platform which was spun out from research that was commercialised as a joint collaboration between the University of Oxford and the University of Cambridge in 1996. It is anticipated that this acquisition will strengthen the company’s foothold in the Proteomics market and provide its customers added flexibility to leverage this exciting technology to model the immune system.
Professor Jonathan Blackburn, Sengenics Chief Scientific Advisor said, "The role of immune system dysfunction in cancers, as well as in acute responses in microbial infections and failed drug clinical trials, is increasingly well recognised today, as evidenced by recent high profile publications in major journals. In addition, many other conditions, including Autism, Parkinson’s and metabolic disorders, are also thought to result from abnormal autoimmune responses. The broad clinical applications of the Immunome™ protein array in profiling and quantifying differential autoimmune responses in disease and treatment therefore convinced Sengenics to acquire this unique technology from OGT.”
Sengenics has already utilised the Immunome™ technology with a very high success rate for more than 50 studies in the USA, Europe and Asia. Most collaborators have moved on to validate their findings and establish IP positions relating to protein biomarkers.
Dr. Mike Evans, CEO of OGT commented, “The protein array platform offers a unique approach for the identification of biomarkers for human disease. We are delighted that Sengenics recognizes the scientific value of this proteomics technology, which was outside of OGT’s strategic focus on genomic products.”
The Immunome™ protein array is the only protein array platform in the world where every protein is full-length, correctly folded and functionally validated. The patented use of the BCCP tag ensures that only correctly folded proteins are immobilised on a solid surface. Key applications of the technology include monitoring differential immune response to drugs and vaccines in clinical trials, as well as modelling viral or bacterial infection. In addition, diagnostic biomarkers can be discovered for any disease that involves the immune system, such as cancer, neurodegenerative and autoimmune disorders.
Sengenics will be offering Immunome™ both as a product and as a service. Immunome protein microarray slides and associated reagents, and software will be available for purchase by customers to run in their own lab. Customers can also choose to send samples to one of Sengenics labs. Patents and/or biomarkers can also be licensed and used for a defined disease or purpose.
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™, and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.
About Sengenics
Sengenics is a genomics and proteomics-based research and diagnostics company, with a range of patented technologies and products that are marketed to pharmaceutical companies, scientists and hospitals. Its flagship technology is the patented Immunome™ auto-antibody profiling platform which was spun out from research that was commercialised as a joint collaboration between the University of Oxford and the University of Cambridge in 1996. It also has additional patented and proprietary products for Human diseases that use the ThalaSURE™ and Genoverse™ brand names. To date Sengenics has carried out the highest number of clinical genomics tests on children with developmental delay in Asia. This has been commercialised into GalaxC™, which is the largest commercial database of human disease mutations in Asia. GalaxC™ can be accessed free of charge by existing customers.
For more information please contact:
Oxford Gene Technology:
W: http://www.ogt.com
Sengenics:
Johan Poole-Johnson
T: +1 650 273 4770
E: [email protected]
W: http://www.sengenics.com
Johan Poole-Johnson, Sengenics, http://www.sengenics.com, +44 1865 589 888, [email protected]
Share this article